Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients.
作者信息
Zatorski Nicole, Sobie Eric A, Schlessinger Avner
机构信息
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
出版信息
Trends Pharmacol Sci. 2023 May;44(5):318-319. doi: 10.1016/j.tips.2023.02.005. Epub 2023 Mar 12.
Abstract
摘要
相似文献
1
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients.马伐卡坦改善梗阻性肥厚型心肌病患者的症状。
Trends Pharmacol Sci. 2023 May;44(5):318-319. doi: 10.1016/j.tips.2023.02.005. Epub 2023 Mar 12.
2
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.马卡丹特对梗阻性肥厚型心肌病有症状患者超声心动图特征的影响。
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
3
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
5
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
6
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.马卡丹特治疗非梗阻性肥厚型心肌病有症状患者的疗效评估。
J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064.
7
[Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].[玛伐卡坦（Camzyos®）：首个用于治疗梗阻性肥厚型心肌病的肌球蛋白调节剂]
Rev Med Liege. 2024 Feb;79(2):120-128.
8
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.马伐卡坦（CAMZYOS）：用于治疗梗阻性肥厚型心肌病的一流小分子肌球蛋白抑制剂。
Clin Nurse Spec. 2024;38(3):E3. doi: 10.1097/NUR.0000000000000822.
9
Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy.马伐卡坦（CAMZYOS）：用于治疗梗阻性肥厚型心肌病的首款小分子肌球蛋白抑制剂。
Clin Nurse Spec. 2024;38(3):119-121. doi: 10.1097/NUR.0000000000000821.
10
Mavacamten (Camzyos) for obstructive hypertrophic cardiomyopathy.玛伐卡坦（卡姆佐）用于梗阻性肥厚型心肌病。
Med Lett Drugs Ther. 2022 Jun 13;64(1652):89-91.
引用本文的文献
1
Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives.麦卡姆坦（Mavacamten）：一种心肌肌球蛋白抑制剂的临床应用及未来展望
Cureus. 2025 Apr 21;17(4):e82722. doi: 10.7759/cureus.82722. eCollection 2025 Apr.
2
Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.肥厚型心肌病：特别关注马伐卡坦及其在心脏病学领域的未来发展
Biomedicines. 2024 Nov 24;12(12):2675. doi: 10.3390/biomedicines12122675.
3
Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in mice.cMyBP-C磷酸化在小鼠心脏收缩功能障碍中的作用。
J Mol Cell Cardiol Plus. 2024 Jun;8. doi: 10.1016/j.jmccpl.2024.100075. Epub 2024 Apr 4.
本文引用的文献
1
Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential.用于肥厚型心肌病的心肌肌球蛋白抑制剂：揭示其临床潜力
Expert Opin Investig Drugs. 2023 Jan;32(1):1-4. doi: 10.1080/13543784.2023.2166825. Epub 2023 Jan 12.
2
An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.马卡丹特治疗成人有症状梗阻性肥厚型心肌病的评价。
Expert Rev Cardiovasc Ther. 2023 Jan;21(1):5-13. doi: 10.1080/14779072.2023.2159811. Epub 2022 Dec 22.
3
Mavacamten: First Approval.马卡丹特：首次获批
Drugs. 2022 Jul;82(10):1127-1135. doi: 10.1007/s40265-022-01739-7. Epub 2022 Jul 8.
4
Cardiac myosin contraction and mechanotransduction in health and disease.心脏肌球蛋白收缩和机械转导在健康和疾病中的作用。
J Biol Chem. 2021 Nov;297(5):101297. doi: 10.1016/j.jbc.2021.101297. Epub 2021 Oct 9.
5
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
6
Hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病。
Lancet. 2017 Mar 25;389(10075):1253-1267. doi: 10.1016/S0140-6736(16)31321-6. Epub 2016 Nov 30.
7
Review: The ATPase mechanism of myosin and actomyosin.综述：肌球蛋白和肌动球蛋白的ATP酶机制。
Biopolymers. 2016 Aug;105(8):483-91. doi: 10.1002/bip.22853.
Zotero 插件